ATE238427T1 - Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie - Google Patents

Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie

Info

Publication number
ATE238427T1
ATE238427T1 AT96907398T AT96907398T ATE238427T1 AT E238427 T1 ATE238427 T1 AT E238427T1 AT 96907398 T AT96907398 T AT 96907398T AT 96907398 T AT96907398 T AT 96907398T AT E238427 T1 ATE238427 T1 AT E238427T1
Authority
AT
Austria
Prior art keywords
vectors
relates
present
antimicrobial peptides
gene therapy
Prior art date
Application number
AT96907398T
Other languages
English (en)
Inventor
Walter H Guenzburg
David Winder
Robert Michael Saller
Original Assignee
Austrian Nordic Biotherapeutic
Gsf Forschungszentrum Umwelt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Austrian Nordic Biotherapeutic, Gsf Forschungszentrum Umwelt filed Critical Austrian Nordic Biotherapeutic
Application granted granted Critical
Publication of ATE238427T1 publication Critical patent/ATE238427T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Insects & Arthropods (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT96907398T 1995-03-09 1996-03-08 Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie ATE238427T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK24395 1995-03-09
PCT/EP1996/001001 WO1996028563A1 (en) 1995-03-09 1996-03-08 Vectors carrying therapeutic genes encoding antimicrobial peptides for gene therapy

Publications (1)

Publication Number Publication Date
ATE238427T1 true ATE238427T1 (de) 2003-05-15

Family

ID=8091353

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96907398T ATE238427T1 (de) 1995-03-09 1996-03-08 Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie

Country Status (10)

Country Link
US (1) US7022319B1 (de)
EP (1) EP0817858B1 (de)
JP (1) JP3908274B2 (de)
AT (1) ATE238427T1 (de)
AU (1) AU5103996A (de)
DE (1) DE69627644T2 (de)
DK (1) DK0817858T3 (de)
ES (1) ES2198479T3 (de)
PT (1) PT817858E (de)
WO (1) WO1996028563A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1117156C (zh) * 1994-09-02 2003-08-06 Gsf环境与健康研究中心有限公司 非自动失活的定位表达的逆转录病毒载体
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
JP2001517433A (ja) 1997-09-24 2001-10-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 非霊長類レンチウイルスベクターおよびパッケージングシステム
GB2344592B (en) * 1997-09-25 2002-09-11 Oxford Biomedica Ltd Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site
WO1999035280A1 (en) * 1998-01-06 1999-07-15 Bavarian Nordic Research Institute A/S Reconstituting retroviral vector (recon vector) for targeted gene expression
GB9817693D0 (en) * 1998-08-14 1998-10-07 Bridgehead Technologies Limite Virally-mediated targeting of drugs and genetic material
DE19910650A1 (de) * 1999-03-10 2000-09-21 Gsf Forschungszentrum Umwelt Auf HERV-LTR-Sequenzen basierende retrovirale Expressionsvektoren
GB9906615D0 (en) * 1999-03-22 1999-05-19 Oxford Biomedica Ltd Vector
EP2167688A4 (de) * 2007-06-12 2010-07-28 Univ Case Western Reserve Gezielter zelltod
US8653236B2 (en) 2008-07-17 2014-02-18 Inter-K Pty Limited Therapeutic agents

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3854476T2 (de) * 1987-07-06 1996-04-04 Univ Louisiana State Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden.
US4822608A (en) 1987-09-14 1989-04-18 Vespa Laboratories, Inc. Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom or proteinaceous or polypeptide components thereof
AU631554B2 (en) 1988-05-17 1992-12-03 Sloan-Kettering Institute For Cancer Research Retroviral vector
US5658775A (en) * 1988-05-17 1997-08-19 Sloan-Kettering Institute For Cancer Research Double copy retroviral vector
US5124263A (en) * 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
ES2048137T3 (es) * 1989-12-07 1994-10-16 Gsf Forschungszentrum Umwelt Metodo y compuesto para el tratamiento de una infeccion hiv en mamiferos.
US6027722A (en) * 1990-10-25 2000-02-22 Nature Technology Corporation Vectors for gene transfer
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
EP0668781B1 (de) * 1991-10-25 1999-12-29 Sidney Kimmel Cancer Center Lymphokine gentherapie bei krebs in kombination mit tumorantigenen
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
WO1994029437A1 (en) 1993-06-07 1994-12-22 University Of Medicine & Dentistry Of New Jersey Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors
WO1995000178A1 (en) 1993-06-25 1995-01-05 Board Of Regents, The University Of Texas System Pore-forming and superantigen encoding toxin cassettes for gene therapy
AU7321294A (en) * 1993-06-30 1995-01-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, The Transformed eukaryotic cells, and transposon-based transformation vectors
AU692794B2 (en) 1993-08-30 1998-06-18 Baylor College Of Medicine Senescent cell-derived inhibitors of DNA synthesis
WO1995013375A1 (en) 1993-11-10 1995-05-18 The Johns Hopkins University Tumor suppressor waf1
CN1117156C (zh) * 1994-09-02 2003-08-06 Gsf环境与健康研究中心有限公司 非自动失活的定位表达的逆转录病毒载体
WO1996028564A1 (en) 1995-03-09 1996-09-19 Bavarian Nordic Research Institute A/S Novel recombinant dna vectors for gene therapy
GB9510272D0 (en) 1995-05-22 1995-07-19 Isis Innovation Retroviral vectors
JP4119952B2 (ja) 1995-06-27 2008-07-16 バヴァリアン・ノルディック・アクティーゼルスカブ ウイルス粒子産生カプセル化細胞
DE69619683T2 (de) 1995-09-06 2002-09-26 Austrian Nordic Biotherapeutics Ag, Wien Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
EP1025208A2 (de) 1997-10-20 2000-08-09 Universita' Degli Studi Di Padova Verpackungszellinie zur herstellung von pseudotypisiertem mlv
WO1999035280A1 (en) 1998-01-06 1999-07-15 Bavarian Nordic Research Institute A/S Reconstituting retroviral vector (recon vector) for targeted gene expression

Also Published As

Publication number Publication date
DE69627644D1 (de) 2003-05-28
EP0817858B1 (de) 2003-04-23
JPH11503305A (ja) 1999-03-26
AU5103996A (en) 1996-10-02
WO1996028563A1 (en) 1996-09-19
DE69627644T2 (de) 2004-02-19
PT817858E (pt) 2003-09-30
JP3908274B2 (ja) 2007-04-25
US7022319B1 (en) 2006-04-04
ES2198479T3 (es) 2004-02-01
DK0817858T3 (da) 2003-08-11
EP0817858A1 (de) 1998-01-14

Similar Documents

Publication Publication Date Title
ATE238427T1 (de) Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie
ATE298371T1 (de) Nicht-primaten lentivirale vektoren und verpackungssysteme
IL64243A (en) Hybrid human leukocyte interferon type anti-viral polypeptides,their preparation by genetic engineering methods and pharmaceutical compositions containing them
DE69230993D1 (de) Rekombinante viren vektoren zur expression in muskelzellen
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
NZ320889A (en) A p35 protein which binds to and inhibits chemokines
AU596997C (en) Pharmaceutical composition for the treatment of leukopenia
EP0845530A3 (de) Interferon gamma induzierender Faktor
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
MY167485A (en) Recombinant human interferon-like proteins
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
ZA200108414B (en) Akt nucleic acids, polypeptides, and uses thereof.
WO2003016472A3 (en) Hybrid interferon/interferon tau proteins, compositions and methods of use
MY198257A (en) Gene Therapy With Dysferlin Dual Vectors
ATE288488T1 (de) Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
EP0072541A3 (de) Menschliche Leukozyten-Interferone, Verfahren zu deren Mikrobiologischer Herstellung, Zwischenprodukte und diese enthaltende Zusammensetzungen
IT1262545B (it) Sistema di espressione per linee cellulari eucariotiche
WO2023096996A3 (en) Chimeric hsv expressing hil21 to boost anti-tumor immune activity
ATE234929T1 (de) Vektor zur expression von therapeutisch relevanten genen
HUP0104598A1 (hu) Hepatocita-eredetű növekedési faktorból (HGF) és makrofágstimuláló proteinből (MSP) származó rekombináns proteinek
WO2002034882A3 (en) Genes regulating programmed cell death
MX9702205A (es) Gen de la galactocinasa humana.

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 0817858

Country of ref document: EP